Element Biosciences is a multi-disciplinary startup founded in 2017 and focused on innovating genetic analysis tools for the research markets. Our mission is to empower the scientific community with more freedom and flexibility to accelerate our collective impact on humanity. Meet the Element AVITI™ System, a benchtop DNA sequencing platform with unprecedented performance, cost, and flexibility. Our proprietary approach to improving the signal-to-noise ratio allows us to provide groundbreaking innovations in surface chemistry, instrumentation, and biochemistry to drastically decrease the run cost and capital cost while delivering high sequencing data quality. Check out our website today to learn more about AVITI with spec sheets, app notes, sequencing datasets and more. Please visit https://www.elementbiosciences.com/ for more information. | Element Biosciences is advancing the future of drug discovery by enabling high-dimensional multiomic analysis through its next-generation AVITI24™ platform. Founded in 2017, Element is committed to empowering researchers with flexible, accessible, and high-performance sequencing technologies. The AVITI24 platform integrates genomic, transcriptomic, proteomic, and cytoprofiling data into a single workflow—delivering a comprehensive view of cellular systems at single-cell resolution. Powered by Element’s proprietary Avidite™ chemistry, AVITI24 offers exceptional data quality, cost efficiency, and scalability to accelerate biomarker discovery, target validation, and therapeutic development. With a mission to remove barriers to discovery, Element is helping scientists generate deeper insights into biology and uncover new possibilities for improving human health. Learn more at elementbiosciences.com
Eclipsebio
Eclipsebio is a biotechnology company delivering sequencing-powered technologies, analytics, and platforms to advance RNA-based and RNA-targeting therapies. From early discovery through preclinical development, Eclipsebio helps researchers generate deep, functional insight into RNA biology to support target discovery, optimization, and validation. Eclipsebio partners with biopharma and academic teams through end-to-end collaborations and specialized project-based services. Learn more at www.eclipsebio.com
EarlyDiagnostics (EarlyDx)
EarlyDx is an epigenomics company advancing methylation-based liquid biopsy solutions to enable earlier detection, tissue-of-origin determination, and tumor-agnostic and variant-independent minimal residual disease (MRD) monitoring. Our proprietary MethylScan™ platform is a next-generation epigenomic platform that enables blood-based biomarker discovery, patient stratification, and clinical trial optimization.
E-BIOT BIOSCIENCE INC.
At e-BLOT, we revolutionized Western blot imaging in 2019 with the launch of the Touch Imager. This innovative chemiluminescence system offers the highest sensitivity and the broadest quantitative range on the market. Our success is built on dedication, expertise, and experience, as we turn challenges and setbacks into opportunities for innovation. Guided by the belief that no challenge is insurmountable, we continuously push the boundaries of imaging technology to meet and exceed our customers’ evolving needs.
Dovetail Genomics
Dovetail Genomics is enabling researchers and clinicians to solve tomorrow’s most challenging scientific problems through novel, multiomic approaches that unlock access to genomic information at unprecedented levels. Combining propriety technologies with platform solutions, services, and cutting-edge bioinformatics and software, our unique approaches are solving complex problems, including chromatin topology analysis, small and large somatic variant detection, de novo chromosome assembly, and haplotype phasing. Our customers are positively impacting the fields of epigenetics, developmental biology, cancer research, evolutionary biology, infectious disease, and more. Dovetail Genomics is based in Scotts Valley, California and Cambridge, Massachusetts.
Discovery Life Sciences
Discovery Life Sciences is a global leader in biospecimens and specialty lab services, enabling the discovery and development of groundbreaking therapeutics and diagnostics. With a robust portfolio of human biospecimens and cellular starting material, preclinical ADME-tox solutions, and cutting-edge specialty lab services, we provide our partners with the tools, data and expertise they need to succeed. From genomics and proteomics to cell biology and molecular pathology, our comprehensive service offerings support every phase of the scientific journey, from research through clinical trials. For more information, visit www.dls.com.
DIMA Biotechnology LLC
DIMA Biotechnology LLC accelerates cancer research through innovative membrane protein and monoclonal antibody discovery platforms. We specialize in producing full length, hard-to-express targets such as GPCRs, ion channels, and transporters et al. All our proteins are overexpressed in HEK293 cells to ensure high quality expression with correct PTMS. Our proprietary platforms include: – Synthetic Nanodisc, PeptiNanodisc, and Detergent-based systems: providing pure full length transmembrane proteins purified by affinity chromatography. – VLP (Virus Like Particles), MNP (Membrane Nano Particles), and Exosome-based systems—which present proteins in their native context but are not purified proteins. We offer over 500 Nanodisc products, with 300+ available in stock for next day delivery covering many GPCR and channel proteins. In antibody discovery, we provide both single B cell–derived rabbit mAbs and Nanobody development. We offer 5,000+ prevalidated recombinant mAb sequences targeting 500+ cancer relevant proteins, which are ready for out-licensing and testing. Additional IgG candidates can be screened within six weeks using proprietary B cell libraries. Our mammalian cell display platform supports antibody engineering services including humanization, affinity maturation, and functional screening. DIMA delivers integrated solutions from membrane protein production to antibody optimization to advance cancer research and therapeutic development.
DELFI Diagnostics
DELFI Diagnostics is developing next-generation, blood-based tests that are accurate, accessible and deliver a new way to help detect cancer. Employing advanced machine-learning methods to whole-genome sequencing data, the DELFI platform is built to address the highest-burden health challenges. We prioritize solutions that have the potential to save lives on a global scale, including for historically underserved populations. DELFI’s platform relies on fragmentomics – the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments. FirstLook Lung, for individuals eligible for lung cancer screening, is our first laboratory-developed screening test and can be part of routine blood work. FirstLook Lung uses millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early stage disease, with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA. For more information, visit www.delfidiagnostics.com. | DELFI Diagnostics is developing next-generation, blood-based tests that are accurate, accessible, and deliver a new way to help detect cancer. DELFI tests are built to solve the highest-burden population health issues, including in historically underserved demographics, and have the potential to save lives on a global scale. FirstLook Lung, for individuals eligible for lung cancer screening, is our first laboratory-developed screening test and requires a simple blood draw that can be incorporated with routine blood work. The test is based on fragmentomics, the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments in the blood. The DELFI platform applies advanced machine-learning technology to whole-genome sequencing data to assess individuals’ cfDNA fragments against populations with and without cancer. FirstLook Lung uses these millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early-stage disease, with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA. To learn more about the FirstLook Lung test, visit www.delfidiagnostics.com or www.firstlooktest.com.
DeepKinase
DeepKinase pioneers in proteomics for drug discovery and development, with two leading products, DoTD and DoTK. DoTD solution provides mass spectrometry based quantitative proteomics to assist TPD therapeutics; results are featured in numerous IND filings. DoTK solution offers patented tyrosine phosphoproteomics technology, vital to understand kinase activities and signaling in cancer and immune diseases. DeepKinase is a global front-runner in proteomics analysis, driving novel research, biomarker discovery, and personalized medicine in pharmaceutical industry.
Danaher Life Sciences, LLC
At Danaher we bring together science, technology and operational capabilities to accelerate the real-life impact of tomorrow’s science and technology. We partner with customers across the globe to help them solve their most complex challenges, architecting solutions that bring the power of science to life. Our global teams are pioneering what’s next across Life Sciences, Diagnostics, Biotechnology and beyond. The Life Sciences companies of Danaher include Abcam, Aldevron, Beckman Coulter Life Sciences, Cytiva, Genedata, IDBS, IDT, Leica Biosystems, Leica Microsystems, Molecular Devices, Phenomenex and SCIEX.